2Department of Cardiology, University of Health Sciences, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul-Turkey
3Department of Cardiology, Faculty of Medicine, Baskent University, İstanbul-Turkey
4Department of Cardiology, Faculty of Medicine, Mersin University, Mersin-Turkey
5Turkey Training and Research Hospital, Cardiology Clinic, Ankara-Turkey
6University of Alberta, Department of Medicine and Dentistry, Division of Cardiology, Alberta-Canada
7Department of Cardiology, Istanbul University, Cardiology Institute, İstanbul-Turkey
8Department of Cardiology, Faculty of Medicine, Ege University, İzmir-Turkey
9Department of Cardiology, Faculty of Medicine, Gazi University, Ankara-Turkey
10Department of Cardiology, Faculty of Medicine, Başkent University, Ankara-Turkey
11Department of Cardiology, Faculty of Medicine, Ankara University, Ankara-Turkey
12Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas-Turkey
13Department of Cardiology, Faculty of Medicine, Trakya University, Edirne-Turkey
Abstract
Natriuretic peptides have long been introduced into clinical practice. These biomarkers have certainly been shown to provide useful information in the diagnosis, prognosis and risk stratification in heart failure and also may have a role in the guidance of heart failure therapy. Although, there are some limitations in using of these markers such as lack of specificity, aging, renal dysfunction or obesity, among the huge number of candidates for heart failure biomarkers, only natriuretic peptides are currently widely used in daily clinical practice in heart failure. Recent heart failure guidelines recognize natriuretic peptides as an essential tool in the new diagnostic and therapeutic algorithms. Furthermore, natriuretic peptides are not only used in the diagnosis or prognosis of heart failure, but also these biomarkers are referred to have some potential role in primary prevention, cardio-oncology, advanced heart failure, assessment of response to cardiac resynchronization therapy, pulmonary arterial hypertension, acute coronary syndromes, atrial fibrillation and valvular heart disease. In this article, natriuretic peptides have been reviewed for their updated information and new recommendations in heart failure and also potential role of these biomarkers in the management of various clinical conditions have been addressed in the form of expert opinion based on the available data in the literature.